School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Intellia Therapeutics Inc NTLA

Healthcare · Biotechnology

$13.07last close 2026-10-09 · market cap $1.83B · delayed data

Trailing returns

1M+7.04%
3M-15.35%
6M-5.50%
1Y-48.66%
5Y-89.17%

Basis: Adjusted daily closes.

What it does

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases.

Open NTLA in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies